B
PLX icon

Bailard’s Protalix BioTherapeutics PLX Stock Holding History

Bailard’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
+61,100
New +$129K ﹤0.01% 749
2024
Q1 		– Sell
-68,100
Closed -$121K – 794
2023
Q4 		$121K Buy
+68,100
New +$106K ﹤0.01% 679

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bailard's PLX Position: Q2 2026 in Review

Bailard opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 61,100 shares worth $142K. The stake represents ﹤0.01% of the portfolio and ranks #749 among its holdings. This is a return to the name: Bailard previously reported a position in PLX as recently as Q4 2023.

Bailard first reported a position in PLX in Q4 2023 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Bailard held 61,100 shares of Protalix BioTherapeutics worth $142K as of Q2 2026.
  • Protalix BioTherapeutics was a new Bailard position in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #749 holding.
  • Bailard first reported a position in Protalix BioTherapeutics in Q4 2023 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.